Name: Hospital Acquired Infections, Multidrug Resistant (MDR) Bacteria, Alternative Approaches to Antibiotic Therapy (en Inglés)
SKU: 54770931
Price: 83040.00 CLP
Availability: InStock
Author: Bostik, Pavel ; Kolar, Milan
ISBN: 9783036544182

portada Hospital Acquired Infections, Multidrug Resistant (MDR) Bacteria, Alternative Approaches to Antibiotic Therapy (en Inglés)

Hospital Acquired Infections, Multidrug Resistant (MDR) Bacteria, Alternative Approaches to Antibiotic Therapy (en Inglés)

Formato

Libro Físico

Ilustrado por

Pavel Bostik

Milan Kolar

Editorial

Mdpi AG

Autor

Bostik, Pavel ; Kolar, Milan

Idioma

Inglés

N° páginas

206

Encuadernación

Tapa Dura

Dimensiones

24.4x17x1.8 cm

Peso

0.64 kg.

ISBN13

9783036544182

Categorías

Medicina: cuestiones generales

Hospital Acquired Infections, Multidrug Resistant (MDR) Bacteria, Alternative Approaches to Antibiotic Therapy (en Inglés)

Pavel Bostik (Ilustrado por) · Milan Kolar (Ilustrado por) · Mdpi AG · Tapa Dura

Libro Nuevo Importado

Envío: 12 a 16 días háb.

$ 150.990$ 83.040

-45%

Costos de importación incluídos en el precio ✅

Libro Nuevo

Quedan más de 100 unidades

$ 83.040

Llega entre el 01 Oct y el 07 Oct a Santiago, Región Metropolitana. Seleccionar ubicación

Agregar a lista de deseos

Reseña del libro "Hospital Acquired Infections, Multidrug Resistant (MDR) Bacteria, Alternative Approaches to Antibiotic Therapy (en Inglés)"

Bacterial resistance to known and currently used antibiotics represents a growing issue worldwide. It poses a major problem in the treatment of infectious diseases in general and hospital-acquired infections in particular. This is in part due to the overuse and misuse of antibiotics in past decades, which led to the selection of highly resistant bacteria and even so-called superbugs - multidrug-resistant (MDR) bacteria. Nosocomial infections, particularly, are often caused by MDR bacterial pathogens and the treatment of such infections is very complicated and extensive, often leading to various side effects, including adverse effects on the natural human microbiome. At the same time, the development of novel antibiotics is lagging with very few new ones in the pipeline. Finding viable alternatives to treat such infections may help to overcome these therapeutic issues. This publication brings novel developments in the field of bacterial resistance, mainly in the hospital settings, adequate antibiotic therapy, and identification of compounds useful to battle this growing issue.